OptiBiotix Health plc
("OptiBiotix" or "the Company")
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that Stephen O'Hara, CEO of Optibiotix, will be presenting at an investor evening hosted by Turner Pope Investments Ltd ("TPI") on Monday, 13 May 2019. The event will be held in the City of London and will commence at 5pm.
To register your interest and obtain further details, please contact TPI on [email protected] or call 0203 621 4124.
No new material or trading information will be provided.
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
| || |
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix Health PLC - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.